Brokerages Set Vor Biopharma Inc. (NASDAQ:VOR) Price Target at $66.13

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been assigned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $66.1250.

Several equities research analysts recently commented on VOR shares. Zacks Research upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Wedbush started coverage on shares of Vor Biopharma in a research report on Tuesday, November 25th. They set a “neutral” rating for the company. Citigroup began coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Finally, HC Wainwright cut their price objective on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, November 14th.

Insider Buying and Selling at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 251,518 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $25.22, for a total value of $6,343,283.96. Following the sale, the director directly owned 804,231 shares in the company, valued at $20,282,705.82. This represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 491,349 shares of company stock valued at $12,926,577 over the last ninety days. Insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently made changes to their positions in VOR. Bank of America Corp DE increased its stake in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Vor Biopharma in the 3rd quarter valued at about $230,000. BNP Paribas Financial Markets increased its stake in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after acquiring an additional 5,058 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter worth about $304,000. Finally, Polymer Capital Management HK LTD purchased a new position in shares of Vor Biopharma during the 3rd quarter worth about $1,035,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $16.59 on Wednesday. The firm has a market capitalization of $172.70 million, a price-to-earnings ratio of -0.04 and a beta of 2.02. The business’s 50 day simple moving average is $11.99 and its 200-day simple moving average is $27.24. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).